Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 3/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881022 | 0.92 | PTK6 (0.41) | PTK6ERBB2KMT2AMEN1MAPT | |
| SCHEMBL2881321 | 0.92 | CDK4 (0.41) | PTK6ERBB2KMT2AMEN1MAPT | |
| SCHEMBL2885462 | 0.90 | POLB (0.40) | PTK6ERBB2KMT2AMEN1MAPT | |
| SCHEMBL2886078 | 0.82 | TTBK1 (0.43) | PTK6ERBB2KMT2AMEN1MAPT | |
| SCHEMBL4404315 | 0.77 | AURKA (0.37) | PTK6ERBB2CYP3A4METCCNC | |
| SCHEMBL15541909 | 0.73 | KMT2A (0.43) | PTK6KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL27193278 | 0.72 | MAPT (0.49) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2886241 | 0.72 | MAPT (0.39) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL23081494 | 0.72 | HSPB1 (0.44) | MAPTALDH1A1HTTCYP3A4MET | |
| SCHEMBL5050786 | 0.72 | KDR (0.58) | EGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1742945-B1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-1742945-B1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1742945-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | TYMP, DPYD, HPRT1 | PTK6 1489/4885ERBB2 2301/4885KMT2A 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.